{
  "resourceType": "CodeSystem",
  "id": "shr-oncology-BrcaReceptorStatusCS",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n<p><b>SHR BrcaReceptorStatusCS CodeSystem</b></p>\n<p>Classification of receptor status in breast cancer.</p>\n</div>"
  },
  "url": "http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS",
  "identifier": {
    "system": "http://standardhealthrecord.org",
    "value": "shr.oncology.BrcaReceptorStatusCS"
  },
  "version": "0.0.1",
  "name": "SHR BrcaReceptorStatusCS CodeSystem",
  "title": "SHR BrcaReceptorStatusCS CodeSystem",
  "status": "draft",
  "date": "2017-12-20",
  "publisher": "The MITRE Corporation: Standard Health Record Collaborative",
  "contact": [
    {
      "telecom": [
        {
          "system": "url",
          "value": "http://standardhealthrecord.org"
        }
      ]
    }
  ],
  "description": "Classification of receptor status in breast cancer.",
  "caseSensitive": true,
  "content": "complete",
  "count": 4,
  "concept": [
    {
      "code": "luminal_A",
      "display": "Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy.",
      "definition": "Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy."
    },
    {
      "code": "luminal_B",
      "display": "Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2.",
      "definition": "Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2."
    },
    {
      "code": "HER2_positive",
      "display": "Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2.",
      "definition": "Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2."
    },
    {
      "code": "Triple_negative",
      "display": "Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy.",
      "definition": "Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy."
    }
  ]
}